Theoretically, it is feasible to inhibit the RANKL–RANK interaction directly from the source to suppress osteoclastogenesis and protect against osteoporosis, which has been recognised as a key and promising therapeutic strategy [20, 21, 22]. This evidence concerns the gene TNFRSF11A and osteoporosis.